Clinical Trials Directory

Trials / Completed

CompletedNCT02395159

Reduction of Groin Wound Infections After Vascular Surgery by Using an Incision Management System (IMS)

Reduction of Groin Wound Infections After Vascular Surgery in Patients With Risk Factors by the Use a Negative Pressure Wound Incision Management System (KCI Prevena)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
204 (actual)
Sponsor
RWTH Aachen University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Comparison of the Prevena™ IMS with the standard wound management method of sterile plaster in vascular surgery patients.

Detailed description

Comparison of the Prevena™ IMS with the standard wound management method of sterile plaster in vascular surgery patients. The aim is to demonstrate that the application of the Prevena™ IMS significantly reduces the incidence of postoperative wound infections. The wound infections will be classified according to Szilagyi. The treatment phase begins following vascular surgery with wound management using either the Prevena™ IMS or a standard wound dressing, depending on the group to which the patient was randomly assigned. It involves a minimum stay of 7 and maximum 10 days in hospital.

Conditions

Interventions

TypeNameDescription
DEVICEPrevena™ IMSPrevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system. The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells.
OTHERsterile plaster dressingsstandard wound management method of sterile plaster dressings

Timeline

Start date
2015-07-01
Primary completion
2017-07-01
Completion
2017-10-10
First posted
2015-03-20
Last updated
2017-10-27

Locations

2 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT02395159. Inclusion in this directory is not an endorsement.